Immix Biopharma (IMMX) Competitors $2.41 +0.32 (+15.31%) Closing price 04:00 PM EasternExtended Trading$2.02 -0.39 (-16.14%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. FHTX, PROK, ADCT, RZLT, ANNX, NVCT, AARD, AMRN, MNPR, and DRUGShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Foghorn Therapeutics (FHTX), ProKidney (PROK), ADC Therapeutics (ADCT), Rezolute (RZLT), Annexon (ANNX), Nuvectis Pharma (NVCT), Aardvark Therapeutics (AARD), Amarin (AMRN), Monopar Therapeutics (MNPR), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Foghorn Therapeutics ProKidney ADC Therapeutics Rezolute Annexon Nuvectis Pharma Aardvark Therapeutics Amarin Monopar Therapeutics Bright Minds Biosciences Immix Biopharma (NASDAQ:IMMX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations. Does the MarketBeat Community favor IMMX or FHTX? Foghorn Therapeutics received 36 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 66.20% of users gave Foghorn Therapeutics an outperform vote. CompanyUnderperformOutperformImmix BiopharmaOutperform Votes11100.00% Underperform VotesNo VotesFoghorn TherapeuticsOutperform Votes4766.20% Underperform Votes2433.80% Is IMMX or FHTX more profitable? Immix Biopharma has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -102.68% -80.89% Foghorn Therapeutics -357.53%N/A -30.98% Do analysts recommend IMMX or FHTX? Immix Biopharma currently has a consensus target price of $7.00, suggesting a potential upside of 186.89%. Foghorn Therapeutics has a consensus target price of $12.13, suggesting a potential upside of 186.78%. Given Immix Biopharma's higher probable upside, equities research analysts plainly believe Immix Biopharma is more favorable than Foghorn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Do insiders & institutionals believe in IMMX or FHTX? 11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 55.4% of Immix Biopharma shares are owned by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer IMMX or FHTX? In the previous week, Foghorn Therapeutics had 11 more articles in the media than Immix Biopharma. MarketBeat recorded 13 mentions for Foghorn Therapeutics and 2 mentions for Immix Biopharma. Foghorn Therapeutics' average media sentiment score of 0.04 beat Immix Biopharma's score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, IMMX or FHTX? Immix Biopharma has higher earnings, but lower revenue than Foghorn Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$15.43M-$0.70-3.49Foghorn Therapeutics$22.60M10.43-$98.43M-$1.36-3.11 Which has more volatility and risk, IMMX or FHTX? Immix Biopharma has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.13, suggesting that its stock price is 213% more volatile than the S&P 500. SummaryFoghorn Therapeutics beats Immix Biopharma on 12 of the 18 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.02M$6.49B$5.33B$8.43BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-2.879.1226.8519.75Price / SalesN/A256.15388.74118.67Price / CashN/A65.8538.2534.62Price / Book3.016.436.764.50Net Income-$15.43M$144.21M$3.23B$248.32M7 Day Performance16.75%2.25%1.71%0.48%1 Month Performance42.69%4.39%11.16%13.08%1 Year Performance13.49%-2.71%17.17%7.36% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma1.9419 of 5 stars$2.41+15.3%$7.00+190.5%-9.1%$67.18MN/A-2.849News CoverageHigh Trading VolumeFHTXFoghorn Therapeutics2.4784 of 5 stars$4.21-5.0%$12.13+188.0%-34.7%$234.67M$22.60M-2.19120Analyst RevisionPROKProKidney1.8129 of 5 stars$0.80-0.8%$5.00+525.2%-79.2%$234.10M$76,000.00-1.453Analyst UpgradeGap DownADCTADC Therapeutics2.6865 of 5 stars$2.34+23.8%$7.75+231.2%-47.6%$232.08M$70.84M-0.98310Analyst RevisionHigh Trading VolumeRZLTRezolute2.6258 of 5 stars$3.80+6.4%$12.14+219.5%+33.7%$230.03MN/A-3.1140Analyst DowngradeAnalyst RevisionANNXAnnexon1.8657 of 5 stars$2.09+4.0%$12.50+498.1%-59.0%$229.30MN/A-1.9960Gap DownNVCTNuvectis Pharma2.2081 of 5 stars$10.95+10.9%$17.00+55.3%+65.3%$228.79MN/A-9.448Positive NewsAARDAardvark TherapeuticsN/A$10.43+5.5%$31.25+199.6%N/A$226.29MN/A0.0018Analyst DowngradeAnalyst RevisionGap UpAMRNAmarin0.3615 of 5 stars$10.90+3.0%$7.00-35.8%-38.8%$225.73M$214.11M-121.11360MNPRMonopar Therapeutics2.8933 of 5 stars$36.90-0.7%$55.33+50.0%+1,063.8%$225.64MN/A-18.7310News CoveragePositive NewsAnalyst UpgradeDRUGBright Minds Biosciences3.0207 of 5 stars$31.99-3.1%$83.25+160.2%+2,394.3%$225.34MN/A-188.17N/APositive NewsEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies Foghorn Therapeutics Competitors ProKidney Competitors ADC Therapeutics Competitors Rezolute Competitors Annexon Competitors Nuvectis Pharma Competitors Aardvark Therapeutics Competitors Amarin Competitors Monopar Therapeutics Competitors Bright Minds Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMMX Stock Free IMMX Stock Alerts